Blocking anti-apoptotic BCL-2 proteins or boosting pro-apoptotic ones may make HTLV-1-infected T cells die, limit viral persistence, and support new therapies for ATLL and other HTLV-1 cancers. This evidence concerns the gene BCL2 and cancer.